Measles reimmunization in children seronegative after initial immunization

Gregory A. Poland, Robert M. Jacobson, Aruna M. Thampy, S. Ann Colbourne, Peter C. Wollan, James J. Lipsky, Steven J. Jacobsen

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Objective.-To evaluate the success of measles reimmunization in children without measles antibody after the initial dose of measles vaccine. Design and Setting.-A prospective clinical trial in Olmsted County, Minnesota, and Northern Newfoundland and Labrador in Canada. Subjects.-A total of 130 healthy white, Innu, and Inuit schoolchildren. All subjects had received the post-1980 Moraten measles vaccine 4 to 11 years earlier. Methods.-Children previously identified as measles antibody seronegative or equivocal after 1 dose of measles vaccine were entered into the trial and reimmunized. Measles antibody was measured a minimum of 6 weeks later using a whole-virus IgG measles-specific enzyme-linked immunoassay (EIA). Results.-Of the 130 children reimmunized, 106 (81.5%) became measles antibody seropositive, but 24 children (18.5%) remained seronegative. Younger age at initial immunization (< 13 months vs ≤13 months) was significantly associated with lack of seropositive antibody levels following reimmunization (odds ratio, 3.9; 95% confidence interval, 1.5-9.7). In addition, antibody levels after reimmunization were significantly reduced with increasing time since initial immunization (P=.001). Conclusions.-After 2 doses of measles vaccine, 98.2% of all subjects in this study were seropositive for measles antibody, despite the fact that almost 20% of children did not have measurable antibodies 4 to 11 years following a first dose. These findings suggest that the current public health policy recommending a 2-dose measles immunization strategy, with the second dose given at school entry, will provide high levels of immunity in the community.

Original languageEnglish (US)
Pages (from-to)1156-1158
Number of pages3
JournalJournal of the American Medical Association
Volume277
Issue number14
StatePublished - Apr 9 1997

Fingerprint

Measles
Immunization
Measles Vaccine
Antibodies
Inuits
Newfoundland and Labrador
Measles virus
Public Policy
Health Policy
Immunoenzyme Techniques
Canada
Immunity
Public Health
Immunoglobulin G
Odds Ratio
Clinical Trials
Confidence Intervals

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Poland, G. A., Jacobson, R. M., Thampy, A. M., Colbourne, S. A., Wollan, P. C., Lipsky, J. J., & Jacobsen, S. J. (1997). Measles reimmunization in children seronegative after initial immunization. Journal of the American Medical Association, 277(14), 1156-1158.

Measles reimmunization in children seronegative after initial immunization. / Poland, Gregory A.; Jacobson, Robert M.; Thampy, Aruna M.; Colbourne, S. Ann; Wollan, Peter C.; Lipsky, James J.; Jacobsen, Steven J.

In: Journal of the American Medical Association, Vol. 277, No. 14, 09.04.1997, p. 1156-1158.

Research output: Contribution to journalArticle

Poland, GA, Jacobson, RM, Thampy, AM, Colbourne, SA, Wollan, PC, Lipsky, JJ & Jacobsen, SJ 1997, 'Measles reimmunization in children seronegative after initial immunization', Journal of the American Medical Association, vol. 277, no. 14, pp. 1156-1158.
Poland GA, Jacobson RM, Thampy AM, Colbourne SA, Wollan PC, Lipsky JJ et al. Measles reimmunization in children seronegative after initial immunization. Journal of the American Medical Association. 1997 Apr 9;277(14):1156-1158.
Poland, Gregory A. ; Jacobson, Robert M. ; Thampy, Aruna M. ; Colbourne, S. Ann ; Wollan, Peter C. ; Lipsky, James J. ; Jacobsen, Steven J. / Measles reimmunization in children seronegative after initial immunization. In: Journal of the American Medical Association. 1997 ; Vol. 277, No. 14. pp. 1156-1158.
@article{42b4c32d9cdf4c8ab0884076bab13a9f,
title = "Measles reimmunization in children seronegative after initial immunization",
abstract = "Objective.-To evaluate the success of measles reimmunization in children without measles antibody after the initial dose of measles vaccine. Design and Setting.-A prospective clinical trial in Olmsted County, Minnesota, and Northern Newfoundland and Labrador in Canada. Subjects.-A total of 130 healthy white, Innu, and Inuit schoolchildren. All subjects had received the post-1980 Moraten measles vaccine 4 to 11 years earlier. Methods.-Children previously identified as measles antibody seronegative or equivocal after 1 dose of measles vaccine were entered into the trial and reimmunized. Measles antibody was measured a minimum of 6 weeks later using a whole-virus IgG measles-specific enzyme-linked immunoassay (EIA). Results.-Of the 130 children reimmunized, 106 (81.5{\%}) became measles antibody seropositive, but 24 children (18.5{\%}) remained seronegative. Younger age at initial immunization (< 13 months vs ≤13 months) was significantly associated with lack of seropositive antibody levels following reimmunization (odds ratio, 3.9; 95{\%} confidence interval, 1.5-9.7). In addition, antibody levels after reimmunization were significantly reduced with increasing time since initial immunization (P=.001). Conclusions.-After 2 doses of measles vaccine, 98.2{\%} of all subjects in this study were seropositive for measles antibody, despite the fact that almost 20{\%} of children did not have measurable antibodies 4 to 11 years following a first dose. These findings suggest that the current public health policy recommending a 2-dose measles immunization strategy, with the second dose given at school entry, will provide high levels of immunity in the community.",
author = "Poland, {Gregory A.} and Jacobson, {Robert M.} and Thampy, {Aruna M.} and Colbourne, {S. Ann} and Wollan, {Peter C.} and Lipsky, {James J.} and Jacobsen, {Steven J.}",
year = "1997",
month = "4",
day = "9",
language = "English (US)",
volume = "277",
pages = "1156--1158",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "14",

}

TY - JOUR

T1 - Measles reimmunization in children seronegative after initial immunization

AU - Poland, Gregory A.

AU - Jacobson, Robert M.

AU - Thampy, Aruna M.

AU - Colbourne, S. Ann

AU - Wollan, Peter C.

AU - Lipsky, James J.

AU - Jacobsen, Steven J.

PY - 1997/4/9

Y1 - 1997/4/9

N2 - Objective.-To evaluate the success of measles reimmunization in children without measles antibody after the initial dose of measles vaccine. Design and Setting.-A prospective clinical trial in Olmsted County, Minnesota, and Northern Newfoundland and Labrador in Canada. Subjects.-A total of 130 healthy white, Innu, and Inuit schoolchildren. All subjects had received the post-1980 Moraten measles vaccine 4 to 11 years earlier. Methods.-Children previously identified as measles antibody seronegative or equivocal after 1 dose of measles vaccine were entered into the trial and reimmunized. Measles antibody was measured a minimum of 6 weeks later using a whole-virus IgG measles-specific enzyme-linked immunoassay (EIA). Results.-Of the 130 children reimmunized, 106 (81.5%) became measles antibody seropositive, but 24 children (18.5%) remained seronegative. Younger age at initial immunization (< 13 months vs ≤13 months) was significantly associated with lack of seropositive antibody levels following reimmunization (odds ratio, 3.9; 95% confidence interval, 1.5-9.7). In addition, antibody levels after reimmunization were significantly reduced with increasing time since initial immunization (P=.001). Conclusions.-After 2 doses of measles vaccine, 98.2% of all subjects in this study were seropositive for measles antibody, despite the fact that almost 20% of children did not have measurable antibodies 4 to 11 years following a first dose. These findings suggest that the current public health policy recommending a 2-dose measles immunization strategy, with the second dose given at school entry, will provide high levels of immunity in the community.

AB - Objective.-To evaluate the success of measles reimmunization in children without measles antibody after the initial dose of measles vaccine. Design and Setting.-A prospective clinical trial in Olmsted County, Minnesota, and Northern Newfoundland and Labrador in Canada. Subjects.-A total of 130 healthy white, Innu, and Inuit schoolchildren. All subjects had received the post-1980 Moraten measles vaccine 4 to 11 years earlier. Methods.-Children previously identified as measles antibody seronegative or equivocal after 1 dose of measles vaccine were entered into the trial and reimmunized. Measles antibody was measured a minimum of 6 weeks later using a whole-virus IgG measles-specific enzyme-linked immunoassay (EIA). Results.-Of the 130 children reimmunized, 106 (81.5%) became measles antibody seropositive, but 24 children (18.5%) remained seronegative. Younger age at initial immunization (< 13 months vs ≤13 months) was significantly associated with lack of seropositive antibody levels following reimmunization (odds ratio, 3.9; 95% confidence interval, 1.5-9.7). In addition, antibody levels after reimmunization were significantly reduced with increasing time since initial immunization (P=.001). Conclusions.-After 2 doses of measles vaccine, 98.2% of all subjects in this study were seropositive for measles antibody, despite the fact that almost 20% of children did not have measurable antibodies 4 to 11 years following a first dose. These findings suggest that the current public health policy recommending a 2-dose measles immunization strategy, with the second dose given at school entry, will provide high levels of immunity in the community.

UR - http://www.scopus.com/inward/record.url?scp=0030917173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030917173&partnerID=8YFLogxK

M3 - Article

C2 - 9087472

AN - SCOPUS:0030917173

VL - 277

SP - 1156

EP - 1158

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 14

ER -